Lecture 10 - Lymphoma Flashcards

1
Q

What is lymphoma?

A
  • malignant disease in which lymphocytes proliferate in an uncontrolled manner leading to lymphocyte accumulation in lymph nodes and or in BM
  • results in lymph node enlargement and marrow failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology of lymphoma

A
  • 5th and 6th most common cancers among males and females
  • one of few cancers with rising incidence
  • incidence of NHL in particulat increeases with age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Types of lymphoma

A

B cell lymphomas are much more common than T cell lymphomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Some important facts

A
  • each lymphocyte has one receptor for antigen on its surface and responds to only one antigen
  • this receptor remains unchanged for the whole of the lymphocytes life
  • thus in a lymphoma: all cells share the same receptor
  • if its a B cell, all lymphoma cells express a single type of light chain, or express the same differentiation proteins on their surface
  • if the parent B cell produces antibody, all lymphoma cells produce that same antibody: paraprotein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Two types of lymphoma

A
  • NHL
  • HL

Based on standard morphology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Identifyhing lymphocute population

A
  • histology: small cells, little cytoplasm, dense chromatin
  • flow cytometry: B cell markers, one type of light chain. CD34 marker is for HSC, CD19 for pro-B cell on , CD20 for pre-B cell on
  • karyotype
  • FISH
  • PCR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Gene translocations in lymphoma

A
  • t (14,18): IgH/bcl2 -> apoptosis through bcl2 -> indolent lymphoma
  • t (11:14): IgH/Bcl1 -> cell cycle via cyclin D -> mantle cell lymphoma
  • t(8:14): IgH/c-myc -> cell cycle via cmyc -> Burkitts lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Major classes of NHL

A
  • indolent (low grade, slow growing) -> folllicular, marginal zone, other
  • aggressive (intermediate and high grade, fast growing -> DLBCL, Burkitts, other
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Indolent NHL

A
  • slow growing but often widespread
  • typically asymptomatic
  • watch and wait strategy
  • respond to treatment but relapse
  • not considerable curable
  • can transform to higher grade lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Aggressive NHL

A
  • most often symptomatic at diagnosis
  • quite often localised at diagnosis
  • progress relatively rapidly without treatment
  • death within months to 1-2 years if not treated effectively
  • always aggressively treated in fit patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DLBCL

A
  • diffuse infiltate of large B cells in node
  • patients of all ages
  • 50% curable with chemotherapy, those that relapse progress and die of lymphoma
  • some relapsong patients can be salvaged with a stem cell transplant usually using the patients own stem cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Burkitt’s lymphoma

A
  • aggressive lymphoma with a particular genetic alteration involving a translocation between chromosomes 8 and 14 that justaposes the cmyc oncogene and the iGH gene
  • cells have a high mutation rate
  • starry sky morphology
  • affects all ages and has a predilection to involve the ileum and the NS
  • requires aggressive multiagent chemotherapy that can be curative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Waldenstroms macroglobulinaemia

A
  • indolent lymphoma of lymphoplasmacytoid cells in the BM
  • characterised by the morphology and the presence of an IgM paraprotein
  • frequently associated with a mutation in the Myd88 signalling pathway protein
  • often associated with anemia and splenomegaly
  • not treated aggressively as many cases slow to progress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Surgical biopsy

A
  • cell detail, architecture, flow cytometry, immunohistochemistry and genetics
  • required for accurate diagnosis and classification
  • gold standard
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Core biopsy

A
  • using ultasound or CT scan is used if excision is difficult
  • give limited material and architecture
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fine needle biopsy

A
  • gives only cytology and flow cytometry but never architecture and is inadequate for initial diagnosis
  • can be used as an initial screen to exclude other cancers or to confirm relapse in a case of known lymphoma
17
Q

Immunophenotyping

A
  • important for lymphoma diagnosis and classification
  • detects antigen expression and monoclonality using kappa and lambda
  • can be done on tissue by flow cytometry and immunohistochemistry or on blood and BM using flow cytometry
18
Q

Ann arbor staging system

A

Takes into account

  • number of disease stes
  • presence of disease above or below diaphragm
  • presence of extranodal disease
  • systemic disease
  • used to distnguish local from extensive disease
  • the higher the stage, the worse the outcome
19
Q

CLBCL international prognostic index (IPI)

A

One point per risk factor

  • age >60 yo
  • stages III or IV
  • 2 extranodal sites
  • ECOG performance status >22
  • LDH elevated
  • if score is 0,1 -> 73% 5 year survival rate
  • if score is 4,5 -> 26% 5 year survival rate
20
Q

Treatment

A
  • watch and wait
  • chemotherapy (CHOP)
  • immunotherapy: rituximab
21
Q

CD20

A
  • transmembrane phosphoprotein
  • single extracellular loop
  • natural ligand not identified
  • physiologic function uncertain
  • expressed on most B cell malignancies
  • resistant to internalisation or shedding after ligation by antibody
22
Q

Rituximab: anti-cd20

A
  • binds CD20 molecule present on normal and malignant B cells
  • improves response rate in B cell lymphomas when given in chemotherapy
  • used routinely as maintenance therapy in low grade lymphoma after completion of chemo-immunotherapy where it prolongs survival
  • used routinely in diffuse laarge B cell lymphoma where it improves response rate and overall survival
  • newer anti-cd20 antibodies have been angineered to improve various aspects of target binding and immune cell recruitment
  • also used in many non-lymphoma situations especially where pathological autoantibodies are formed
23
Q

3 potential effects of anti-cd20 on tumour cells

A
  • complement fixation
  • antibody dependent cellular cytotoxicity
  • active signalling
24
Q

Rituximab evidence

A
  • improved the outcome of patients with advanced stage follicular NHL
  • improves overall survival of patients with DLBCL
25
Q

New drug classes emerging in lymphoma

A
  • immunomodulating drugs - lenalidomide
  • proteasome inhibitors - bortezomib
  • B cell receptor signaling inhibitors - ibrutinib, idelalisib
  • BH3 mimetics that induce apoptosis - ABT-199